Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Evolent Health, Inc.EVH · Entity 5492 | Chief Operating Officer | March 01, 2019 | March 05, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Evolent Health, Inc.
Report date March 01, 2019 · Filed March 05, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Leveraged Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 85,594 |
Reported balance
After 2019-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-03-01 · Grant · Acquired 85,594 · Balance 85,594 F1: Each leveraged stock unit ("LSU") represents the contingent right to receive, upon vesting, between 0% and 200% of one share of the Issuer's Class A common stock, subject to the level of achievement of applicable performance conditions. The resulting number of shares acquired upon vesting of the LSUs, if any, is based on the cumulative performance of the Issuer's Class A common stock. F2: These LSUs vest on March 2, 2022 F3: These LSUs do not expire |
Filing footnotes · ownership attribution and instrument terms
F1: Each leveraged stock unit ("LSU") represents the contingent right to receive, upon vesting, between 0% and 200% of one share of the Issuer's Class A common stock, subject to the level of achievement of applicable performance conditions. The resulting number of shares acquired upon vesting of the LSUs, if any, is based on the cumulative performance of the Issuer's Class A common stock.
F2: These LSUs vest on March 2, 2022
F3: These LSUs do not expire
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2019 Filed Mar 5, 2019 21:12 UTC | Evolent Health, Inc. EVH · Entity 5492 | GrantLeveraged Restricted Stock Unit · Derivative | 85,594 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628908-19-000008 · primary_doc.xml · derivative · entry 1 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,594 Underlying: Class A Common Stock · 85,594 shares Expires not disclosed F1 · shares: Each leveraged stock unit ("LSU") represents the contingent right to receive, upon vesting, between 0% and 200% of one share of the Issuer's Class A common stock, subject to the level of achievement of applicable performance conditions. The resulting number of shares acquired upon vesting of the LSUs, if any, is based on the cumulative performance of the Issuer's Class A common stock. F2 · derivative.exercise_date: These LSUs vest on March 2, 2022 F3 · derivative.expiration_date: These LSUs do not expire F1 · derivative.underlying_shares: Each leveraged stock unit ("LSU") represents the contingent right to receive, upon vesting, between 0% and 200% of one share of the Issuer's Class A common stock, subject to the level of achievement of applicable performance conditions. The resulting number of shares acquired upon vesting of the LSUs, if any, is based on the cumulative performance of the Issuer's Class A common stock. Read SEC document |
| September 13, 2018 Filed Sep 14, 2018 20:47 UTC | Evolent Health, Inc. EVH · Entity 5492 | Exercise / conversionClass A Common Stock Option (Right to buy) · Derivative | 70,000 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001628908-18-000070 · primary_doc.xml · derivative · entry 3 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,274 Underlying: Class A Common Stock · 70,000 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F4 · derivative.exercise_date: The Class A Common Stock Options exercised vested on December 1, 2014 and December 1, 2015. Read SEC document |
| September 13, 2018 Filed Sep 14, 2018 20:47 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 70,000 | $27.50 | $1,925,000.00 |
DisclosureSEC source: 0001628908-18-000070 · primary_doc.xml · nonDerivative · entry 2 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,868 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F3 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $27.50-$27.55, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| September 13, 2018 Filed Sep 14, 2018 20:47 UTC | Evolent Health, Inc. EVH · Entity 5492 | Exercise / conversionClass A Common Stock | 70,000 | $3.84 | $268,800.00 |
DisclosureSEC source: 0001628908-18-000070 · primary_doc.xml · nonDerivative · entry 1 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 20:50 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 30,000 | $25.00 | $750,000.00 |
DisclosureSEC source: 0001628908-18-000067 · primary_doc.xml · nonDerivative · entry 1 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,868 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $25.00-$25.025, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 21:15 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 10,000 | $19.96 | $199,600.00 |
DisclosureSEC source: 0001628908-18-000060 · primary_doc.xml · nonDerivative · entry 1 Peterson Thomas III · CIK 0001643498 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,868 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $19.60-$20.40, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 20:38 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 10,000 | $21.21 | $212,100.00 |
DisclosureSEC source: 0001628908-18-000055 · primary_doc.xml · nonDerivative · entry 1 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,868 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · price: The price reported in Column 4 is as weighted average. These shares were sold in multiple transactions at prices ranging from $20.60-$21.55, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 22:01 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 10,000 | $20.04 | $200,400.00 |
DisclosureSEC source: 0001628908-18-000037 · primary_doc.xml · nonDerivative · entry 1 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,868 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $19.65-$20.40, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate prices within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| May 14, 2018 Filed May 16, 2018 20:31 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 10,000 | $18.91 | $189,100.00 |
DisclosureSEC source: 0001628908-18-000033 · primary_doc.xml · nonDerivative · entry 1 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,868 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $18.65-$19.00, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 22:32 UTC | Evolent Health, Inc. EVH · Entity 5492 | GrantClass A Common Stock Option (right to buy) · Derivative | 58,923 | $0.00 Strike: $13.95 | $0.00 |
DisclosureSEC source: 0001628908-18-000007 · primary_doc.xml · derivative · entry 2 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,923 Underlying: Class A Common Stock · 58,923 shares Expires 2028-02-01 F4 · derivative.exercise_date: Securities vest at a rate of 25% annually beginning February 1, 2019. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 22:32 UTC | Evolent Health, Inc. EVH · Entity 5492 | GrantClass A Common Stock | 25,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-18-000007 · primary_doc.xml · nonDerivative · entry 1 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,868 F1 · security: Represents restricted stock units granted to Mr. Peterson pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest at a rate of 25% annually beginning February 1, 2019. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 24, 2017 Filed Jul 26, 2017 20:43 UTC | Evolent Health, Inc. EVH · Entity 5492 | Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 14,033 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001628908-17-000037 · primary_doc.xml · derivative · entry 4 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,274 Underlying: Class A Common Stock · 14,033 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 24, 2017. F5 · derivative.exercise_date: The Class A Common Stock Options vested on December 1, 2014. Read SEC document |
| July 24, 2017 Filed Jul 26, 2017 20:43 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 26,507 | $26.00 | $689,182.00 |
DisclosureSEC source: 0001628908-17-000037 · primary_doc.xml · nonDerivative · entry 3 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,778 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 24, 2017. F4 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $26.00-$26.025, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 24, 2017 Filed Jul 26, 2017 20:43 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 14,033 | $26.00 | $364,858.00 |
DisclosureSEC source: 0001628908-17-000037 · primary_doc.xml · nonDerivative · entry 2 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,285 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 24, 2017. F3 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $26.00-$26.025, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 24, 2017 Filed Jul 26, 2017 20:43 UTC | Evolent Health, Inc. EVH · Entity 5492 | Exercise / conversionClass A Common Stock | 14,033 | $3.84 | $53,886.72 |
DisclosureSEC source: 0001628908-17-000037 · primary_doc.xml · nonDerivative · entry 1 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,318 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 24, 2017. F2 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| May 19, 2017 Filed May 23, 2017 22:27 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 57,433 | $24.30 | $1,395,621.90 |
DisclosureSEC source: 0000950157-17-000722 · form4.xml · nonDerivative · entry 1 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,285 F1 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| May 15, 2017 Filed May 17, 2017 22:42 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 20,777 | $24.99 | $519,217.23 |
DisclosureSEC source: 0001643498-17-000003 · primary_doc.xml · nonDerivative · entry 4 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,761 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2017. F5 · price: The price reported in Column4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $24.85-$25.35, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 15, 2017 Filed May 17, 2017 22:42 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 20,777 | $24.99 | $519,217.23 |
DisclosureSEC source: 0001643498-17-000003 · primary_doc.xml · nonDerivative · entry 3 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,538 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2017. F4 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $24.85-$25.35, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 15, 2017 Filed May 17, 2017 22:42 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 20,777 | $24.99 | $519,217.23 |
DisclosureSEC source: 0001643498-17-000003 · primary_doc.xml · nonDerivative · entry 2 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,315 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2017. F3 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $24.90-$25.35, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 15, 2017 Filed May 17, 2017 22:42 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 20,777 | $25.00 | $519,425.00 |
DisclosureSEC source: 0001643498-17-000003 · primary_doc.xml · nonDerivative · entry 1 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,092 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2017. F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $24.90-$25.35, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 12, 2017 Filed May 16, 2017 22:09 UTC | Evolent Health, Inc. EVH · Entity 5492 | Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 9,328 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001643498-17-000002 · primary_doc.xml · derivative · entry 4 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,307 Underlying: Class A Common Stock · 9,328 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2016. F3 · derivative.exercise_date: The Class A Common Stock Options exercised began vesting at a rate of 25% annually beginning December 1, 2014. Read SEC document |
| May 12, 2017 Filed May 16, 2017 22:09 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 17,114 | $25.00 | $427,850.00 |
DisclosureSEC source: 0001643498-17-000002 · primary_doc.xml · nonDerivative · entry 3 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,869 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2016. F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $25.00-$25.05, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 12, 2017 Filed May 16, 2017 22:09 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 9,328 | $25.00 | $233,200.00 |
DisclosureSEC source: 0001643498-17-000002 · primary_doc.xml · nonDerivative · entry 2 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,983 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2016. Read SEC document |
| May 12, 2017 Filed May 16, 2017 22:09 UTC | Evolent Health, Inc. EVH · Entity 5492 | Exercise / conversionClass A Common Stock | 9,328 | $3.84 | $35,819.52 |
DisclosureSEC source: 0001643498-17-000002 · primary_doc.xml · nonDerivative · entry 1 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 388,311 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2016. Read SEC document |
| May 10, 2017 Filed May 12, 2017 23:18 UTC | Evolent Health, Inc. EVH · Entity 5492 | Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 6,265 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001643498-17-000001 · primary_doc.xml · derivative · entry 4 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,635 Underlying: Class A Common Stock · 6,265 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2016. F4 · derivative.exercise_date: The Class A Common Stock Options exercised began vesting at a rate of 25% annually beginning December 15, 2014. Read SEC document |
| May 10, 2017 Filed May 12, 2017 23:18 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 12,339 | $25.00 | $308,475.00 |
DisclosureSEC source: 0001643498-17-000001 · primary_doc.xml · nonDerivative · entry 3 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,983 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2016. F3 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $25.00-$25.025, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 10, 2017 Filed May 12, 2017 23:18 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 6,265 | $25.00 | $156,625.00 |
DisclosureSEC source: 0001643498-17-000001 · primary_doc.xml · nonDerivative · entry 2 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 391,322 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2016. F2 · price: The price reported in Column 4 is a weighted average. These shares sold in multiple transactions at prices ranging from $25.00-$25.025, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 10, 2017 Filed May 12, 2017 23:18 UTC | Evolent Health, Inc. EVH · Entity 5492 | Exercise / conversionClass A Common Stock | 6,265 | $3.84 | $24,057.60 |
DisclosureSEC source: 0001643498-17-000001 · primary_doc.xml · nonDerivative · entry 1 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 395,587 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2016. Read SEC document |
| February 01, 2017 Filed Feb 4, 2017 00:33 UTC | Evolent Health, Inc. EVH · Entity 5492 | GrantClass A Common Stock Option (right to buy) · Derivative | 30,637 | $0.00 Strike: $18.25 | $0.00 |
DisclosureSEC source: 0000950157-17-000196 · form4.xml · derivative · entry 2 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,637 Underlying: Class A Common Stock · 30,637 shares Expires 2027-02-01 F3 · derivative.exercise_date: Securities vest at a rate of 25% annually beginning February 1, 2018. Read SEC document |
| February 01, 2017 Filed Feb 4, 2017 00:33 UTC | Evolent Health, Inc. EVH · Entity 5492 | GrantClass A Common Stock | 13,699 | $0.00 | $0.00 |
DisclosureSEC source: 0000950157-17-000196 · form4.xml · nonDerivative · entry 1 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 391,322 F1 · security: Represents restricted stock units granted to Mr. Peterson pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation plan. F2 · shares: Securities vest at a rate of 25% annually beginning February 1, 2018. Read SEC document |
| September 14, 2016 Filed Sep 15, 2016 20:50 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 72,827 | $21.54 | $1,568,693.58 |
DisclosureSEC source: 0000950157-16-002177 · form4.xml · nonDerivative · entry 1 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377,623 F1 · price: The price of $21.54 represents the public offering price of $22.50 per share of Class A Common Stock less the underwriters' discount of $0.96 per share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.